Nanjing Leads Biolabs Doses First Subject in Phase I Trial of Autoimmune Drug LBL-047

The latest update is out from Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ).

Nanjing Leads Biolabs has begun dosing the first subject in a Phase I clinical trial of LBL-047, a bispecific fusion protein designed to treat systemic lupus erythematosus and potentially other autoimmune diseases by simultaneously targeting plasmacytoid dendritic cells and B-cell activation pathways. The randomized, double-blind, placebo-controlled single-ascending-dose study in healthy adults and SLE patients, conducted at leading Shanghai medical centers, marks a significant milestone in the clinical development of LBL-047 and follows the company’s global licensing deal with U.S.-listed Dianthus Therapeutics, which holds exclusive rights to develop and commercialize the drug outside Greater China under the name DNTH212, potentially strengthening Nanjing Leads Biolabs’ international footprint and future revenue prospects through substantial milestone payments.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

More about Nanjing Leads Biolabs Co., Ltd. Class H

Nanjing Leads Biolabs Co., Ltd. is a China-based biopharmaceutical company focused on developing innovative biologic therapies for autoimmune diseases. Its pipeline includes advanced antibody and fusion-protein drug candidates targeting key immune pathways, with an emphasis on global partnerships to commercialize its products outside Greater China.

Average Trading Volume: 628,345

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$9.98B

For detailed information about 9887 stock, go to TipRanks’ Stock Analysis page.